Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT03122509
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT03122496
- Locations
- 🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering @ Rockville, Rockville Centre, New York, United States
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 45
- Registration Number
- NCT03102047
- Locations
- 🇺🇸
Smilow Cancer Hospital Care Center at Trumbull, Trumbull, Connecticut, United States
🇺🇸Strecker Cancer Center, Belpre, Ohio, United States
🇺🇸Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
Durvalumab in HIV-1 Patients With Solid Tumors
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Spanish Lung Cancer Group
- Target Recruit Count
- 20
- Registration Number
- NCT03094286
- Locations
- 🇪🇸
H. La Paz, Madrid, Spain
🇪🇸Hospital La Fe, Valencia, Spain
🇪🇸Hospital Virgen del Rocío, Sevilla, Spain
Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
- Conditions
- Interventions
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Target Recruit Count
- 123
- Registration Number
- NCT03095274
- Locations
- 🇪🇸
Instituto Catalán de Oncología Badalona, Badalona, Barcelona, Spain
🇪🇸Hospital Duran i Reynals/ICO L'Hospitalet, Barcelona, Spain
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Biomarker-based Study in R/M SCCHN
- Conditions
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2023-11-03
- Target Recruit Count
- 340
- Registration Number
- NCT03088059
- Locations
- 🇧🇪
CHU Saint-Pierre-Site Porte de Hal, Brussels, Belgium
🇮🇹IRCCS - Fondazione G. Pascale, Napoli, Italy
🇬🇧Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
- Conditions
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Catherine Shu
- Target Recruit Count
- 2
- Registration Number
- NCT03085849
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2021-05-14
- Target Recruit Count
- 36
- Registration Number
- NCT03081923
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT03075527
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 301
- Registration Number
- NCT03057106
- Locations
- 🇨🇦
Regional Health Authority B, Zone 2, Saint John, New Brunswick, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
🇦🇺Coffs Habour Health Campus - NCCI, Coffs Harbour, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.